Check out Siren Biotechnology & WhiteLab Genomics featured in Cell & Gene by Tyler Menichiello: "There had never been an AAV in oncology before, and so we got excited about just testing these as a use case,” Nicole K. Paulk, PhD says. This testing ultimately turned into Siren’s lead technology platform, its universal immuno-gene therapy." "In addition to testing, Paulk says, Siren relies on artificial intelligence to predict the most-promising indication. The company is collaborating with WhiteLab Genomics and utilizing its AI-powered platform to accelerate the identification of new indications."
Exciting work Siren Biotechnology, WhiteLab Genomics, Nicole K. Paulk, PhD, & David Del Bourgo!
Thank you for sharing!
CEO & Founder of Siren Biotechnology
1moTeamwork makes the dream work! Excited to be working on this with the WhiteLab Genomics team! 🌟